Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03472495 · ClinicalTrials.gov registry record · Phase 4
Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial
A Phase 4 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT03472495 is a Phase 4 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 19 participants.
The verdict
NCT03472495, a Phase 4 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the incidence of rate control (defined as: HR \<110 beats/min or conversion to sinus rhythm) at 2 hours after medication administration between oral immediate release diltiazem and intravenous continuous infusion diltiazem.
Interventions
- DRUG Diltiazem Oral Product
- DRUG Diltiazem Injectable Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2021-03-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03472495
The ClinicalTrials.gov registry entry for NCT03472495 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Diltiazem Oral Product is the first listed.
NCT03472495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03472495 about?
NCT03472495 is a clinical study titled "Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial". The primary objective of this study is to compare the incidence of rate control (defined as: HR \<110 beats/min or conversion to sinus rhythm) at 2 hours after medication administration between oral immediate release diltiazem and intravenous continuous infusion diltiazem.
What is the current status of trial NCT03472495?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2018-06-01. Estimated completion is 2021-03-21.
What interventions are being tested in trial NCT03472495?
The interventions under investigation include: Diltiazem Oral Product (DRUG), Diltiazem Injectable Product (DRUG).
Who is sponsoring clinical trial NCT03472495?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.